Talphera (NASDAQ:TLPH) Now Covered by Analysts at Maxim Group

Stock analysts at Maxim Group initiated coverage on shares of Talphera (NASDAQ:TLPH) in a research note issued to investors on Monday, Benzinga reports. The brokerage set a “buy” rating and a $3.00 price target on the stock. Maxim Group’s price objective points to a potential upside of 202.69% from the stock’s current price.

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Talphera in a research note on Thursday, March 7th.

Talphera Stock Down 3.8 %

Talphera stock opened at $0.99 on Monday. Talphera has a 1 year low of $0.43 and a 1 year high of $1.61. The company has a 50 day moving average of $1.10. The stock has a market cap of $16.84 million, a P/E ratio of -0.67 and a beta of 0.46.

Talphera (NASDAQ:TLPH) last announced its earnings results on Wednesday, March 6th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The company had revenue of $0.28 million during the quarter. As a group, equities research analysts forecast that Talphera will post -1.12 earnings per share for the current year.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.